Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

myofunctional research co - 47526 - mandible-repositioning antisnoring orthosis - oral appliance used in the treatment of alleviating snoring and other breathing disorders by posturing the lower jaw forward and opening the bite which opens the airway and helps prevent snoring

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

myofunctional research co - 35310 - orthodontic appliance, retainer - used to maintain teeth in corrected positions during the period of functional adaptation following corrective treatment. these appliances are also used to maintain the positions of the teeth and jaws effected by orthodontic procedure

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

algostim research & development pty limited - 60959 - analgesic pens system - the neurostimulator pens therapy pain management system is intended for selectively stimulating peripheral nerves, for the symptomatic relief of chronic peripheral neuropathic pain, as determined by a suitably qualified pain management physician in a clinical setting only. stimulation is typically delivered for between 2 and 25 minutes and repeated if required or indicated by the physician.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

algostim research & development pty limited - 36957 - probe, stimulator - pens therapy probes are sterile for single use and are used in conjunction with an algotec pens therapy device. a re-usable, non-sterile intermediate cable is the interface between the probe and the device. probes are intended for the transfer of electrical stimulus, generated from the algotec pens therapy device and delivered to peripheral nerves. the stimulation field remains local to the probe, the stimulation source, therefore larger areas may require the use of a longer length probe, two probes or a repeated procedure. pens therapy probes are only intended for use by a trained physician and only in a clinical setting.

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

antisoma research limited - fludarabine phosphate (unii: 1x9vk9o1sc) (fludarabine - unii:p2k93u8740) - tablet, film coated - 10 mg - fludarabine phosphate is indicated as a single agent for the treatment of adult patients with b-cell chronic lymphocytic leukemia (cll) whose disease has not responded to or has progressed during or after treatment with at least one standard alkylating-agent containing regimen. studies demonstrating clinical benefit such as prolongation of survival or relief of symptoms have not been performed. studies providing a direct comparison of the clinical efficacy and safety of orally administered fludarabine phosphate relative to intravenously administered fludarabine phosphate have not been performed. none “pregnancy category d. see ‘ warnings and precautions ’ section.” based on its mechanism of action, fludarabine phosphate can cause fetal harm when administered to a pregnant woman. there are no adequate and well-controlled studies of fludarabine phosphate in pregnant women. fludarabine phosphate was embryolethal and teratogenic in both rats and rabbits. if fludarabine phosphate is used during pregnancy, or if

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

sun pharma advanced research company limited - levetiracetam (unii: 44yrr34555) (levetiracetam - unii:44yrr34555) - levetiracetam 1000 mg - elepsia xr is indicated as adjunctive therapy for the treatment of partial-onset seizures in patients 12 years of age and older. elepsia xr is contraindicated in patients with a hypersensitivity to levetiracetam. reactions have included anaphylaxis and angioedema [see warnings and precautions (5.4) ]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs (aeds), including elepsia xr, during pregnancy. encourage women who are taking elepsia xr during pregnancy to enroll in the north american antiepileptic drug (naaed) pregnancy registry by calling 1-888-233-2334 or visiting http://www.aedpregnancyregistry.org/. risk summary prolonged experience with levetiracetam in pregnant women has not identified a drug-associated risk of major birth defects or miscarriage, based on published literature, which includes data from pregnancy registries and reflects experience over two decades [see human data ] . in animal studies, levetirac

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

rubicon research private limited - metoprolol tartrate (unii: w5s57y3a5l) (metoprolol - unii:geb06nhm23) - metoprolol tartrate 100 mg - hypertension metoprolol tartrate tablets are indicated for the treatment of hypertension. they may be used alone or in combination with other antihypertensive agents. angina pectoris metoprolol tartrate tablets are indicated in the long-term treatment of angina pectoris. myocardial infarction metoprolol tartrate tablets are indicated in the treatment of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality when used alone or in conjunction with intravenous metoprolol. oral metoprolol tartrate tablets therapy can be initiated after intravenous metoprolol therapy or, alternatively, oral treatment can begin within 3 to 10 days of the acute event. (see dosage and administration, contraindications and warnings). hypertension and angina metoprolol tartrate tablets are contraindicated in sinus bradycardia, heart block greater than first degree, cardiogenic shock, and overt cardiac failure (see warnings). hypersensitivity to metoprolol and related de

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

tai guk pharm. co., ltd. - bacitracin zinc (unii: 89y4m234es) (bacitracin - unii:58h6rwo52i) - bacitracin 500 [usp'u] in 1 g - uses first aid to help prevent infection in minor - cuts - scraps - burns do not use - in the eyes - if you are allergic to any of the ingredients - over large areas of the body - longer than 1 week unless directed by a doctor stop use and ask a doctor if - the condition persists or gets worse - a rash or other allergic reaction develops directions - clean the affected area - apply a small amount of this product (an amount equal to the surface area of the tip of a finger) on the area 1 to 3 times daily - may be covered with a sterile bandage

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

united research laboratories, inc. - methimazole (unii: 554z48xn5e) (methimazole - unii:554z48xn5e) - tablet - 5 mg - methimazole is indicated in the medical treatment of hyperthyroidism. long-term therapy may lead to remission of the disease. methimazole may be used to ameliorate hyperthyroidism in preparation for subtotal thyroidectomy or radioactive iodine therapy. methimazole is also used when thyroidectomy is contraindicated or not advisable. methimazole is contraindicated in the presence of hypersensitivity to the drug and in nursing mothers because the drug is excreted in milk.

Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

alissa healthcare research limited - buprenorphine - transdermal patch - 5 microgram per hour - oripavine derivatives; buprenorphine